Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JUN | P05412 | 19/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 19/20 | 1.00 |
| ▸ | NFKB2 | Q00653 | 19/20 | 1.00 |
| ▸ | RELA | Q04206 | 19/20 | 1.00 |
| ▸ | FOS | P01100 | 12/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL541944 | 0.78 | JUN (0.63) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL8396932 | 0.77 | KDM4E (0.70) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL3922065 | 0.73 | KDM4E (1.00) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL2119119 | 0.73 | KDM4E (0.74) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL5928385 | 0.72 | JUN (0.57) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL4592592 | 0.72 | KDM4E (0.72) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL8543216 | 0.72 | KDM4E (0.72) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL25415290 | 0.71 | KDM4E (0.71) | JUNNFKB1NFKB2RELAFOS | |
| Water SCHEMBL4592788 | 0.71 | KDM4E (0.71) | JUNNFKB1NFKB2RELAFOS | |
| SCHEMBL30617280 | 0.71 | KDM4E (0.71) | JUNNFKB1NFKB2RELAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2827890-B1 | IMMUNOMODULATORY AGENT AND USES THEREFOR | UNIV QUEENSLAND (AU) | 2019-08-28 | — | — | EP | disclosed |
| EP-2077821-B1 | COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES | UNIV QUEENSLAND (AU) | 2019-08-14 | — | — | EP | disclosed |
| US-8969397-B2 | Systems and methods to treat pain locally | WARSAW ORTHOPEDIC, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8829014-B2 | Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2014-09-09 | — | — | US | disclosed |
| EP-2007393-B1 | THIAZOLE AND THIOPHENE ANALOGUES, AND THEIR USE IN TREATING AUTOIMMUNE DISEASES AND CANCERS | UNIV LOUISIANA STATE (US) | 2013-08-21 | — | — | EP | disclosed |
| CN-101646418-B | Compositions and methods for modulating immune responses | UNIV QUEENSLAND | 2013-07-17 | — | — | CN | disclosed |
| US-20120283268-A1 | Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers | GIORDANO ANTHONY (US) | 2012-11-08 | — | — | US | disclosed |
| US-8217037-B2 | Thiazole and thiophene analogues, and their use in treating autoimmune diseases and cancers | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2012-07-10 | — | — | US | disclosed |
| US-20110268722-A1 | COMBINATION THERAPIES WITH MITOCHONDRIAL-TARGETED ANTI-TUMOR AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-11-03 | — | — | US | disclosed |
| CN-101646418-A | Compositions and methods for modulating immune responses | UNIV QUEENSLAND AU | 2010-02-10 | — | — | CN | disclosed |
| US-20090306073-A1 | Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers | B.V. PATEL PHARMACEUTICAL EDUCATION & RESEARCH DEVELOPMENT (PERD) CENTRE (IN) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110268722-A1 | COMBINATION THERAPIES WITH MITOCHONDRIAL-TARGETED ANTI-TUMOR AGENTS | TFAM, AIFM1, MAVS | JUN 1267/4885NFKB1 163/4885NFKB2 111/4885 |
| US-20090306073-A1 | Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers | TPMT, TST, SSB | JUN 2228/4885NFKB1 1188/4885NFKB2 1441/4885 |
| US-20120283268-A1 | Thiazole and Thiophene Analogues, and Their Use in Treating Autoimmune Diseases and Cancers | TPMT, TST, SSB | JUN 2228/4885NFKB1 1188/4885NFKB2 1441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.